Studieninformationen
Kurztitel:
Chaplin
Beschreibung:
Multicenter Study to Evaluate the Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic Non-squamous NSCLC or Extensive-stage SCLC Under First-line Treatment With Atezolizumab and Platinum-based Chemotherapy
Studiendesign:
N/A, , Monozentrisch, National
Alter:
>= 18 Jahre
Erkrankungen:
Ein-/Ausschlusskriterien:
Inclusion criteria Histologically or cytologically confirmed stage IV non-squamous NSCLC or histologically or cytologically confirmed extensive-stage SCLC or histologically or cytologically confirmed advanced (locally advanced and inoperable or metastatic), PD-L1 IC-positive TNBC, respectively Indication and decision for approved therapy with atezolizumab and bevacizumab in combination with carboplatin and paclitaxel induction followed by atezolizumab/bevacizumab maintenance therapy in accordance with the current German SmPC of atezolizumab for first-line treatment of stage IV non-squamous NSCLC atezolizumab in combination with carboplatin and nab-paclitaxel induction followed by atezolizumab maintenance therapy in accordance to the current German SmPC of atezolizumab for first-line treatment of stage IV non-squamous NSCLC atezolizumab in combination with carboplatin and etoposide induction followed by atezolizumab maintenance therapy in accordance to the current German SmPC of atezolizumab for first-line treatment of extensive-stage SCLC atezolizumab in combination with nab-paclitaxel in accordance to the current German SmPC of atezolizumab for treatment of advanced, PD-L1 IC-positive TNBC Aged ≥ 18 years ECOG 0-2 In possession of a web-connected, frequently used, electronic device (smartphone, tablet, PC) Willingness and ability to participate at the paper-based or digital questionnaire project and to participate at an initial training and to regularly use the web-based application tool CANKADO Fluent in written and spoken German Written (signed and dated) informed consent Exclusion Criteria: Prior treatment for stage IV non-squamous NSCLC (prior TKI therapy is allowed for EGFR mutant or ALK-positive NSCLC) or prior systemic treatment for extensive-stage SCLC or prior systemic chemotherapy for advanced TNBC History of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation Pregnant or breast-feeding women
NCT-Nummer:
Studienaktive Standorte
MVZ am Klinikum Aschaffenburg-Alzenau
MVZ Klinikum Aschaffenburg-Alzenau, Onkologie Aschaffenburg
Rekrutierung läuft
Herr Dr. Manfred Welslau
m.welslau@onkologie-ab.de
Thoraxzentrum Unterfranken, Münnerstadt
Thoraxzentrum Bezirk Unterfranken, Münnerstadt
Rekrutierung läuft
Herr Dr. Bernd Seese
B.Seese@tzbu.de